Found 1 Presentation For Request "2401P"
2401P - Detection of molecular recurrence in early-stage bladder cancer patients using a urinary tumor DNA assay after transurethral resection of bladder tumor (TURBT)
- Ruiyun Zhang (Shanghai, China)
Abstract
Background
Transurethral resection of bladder tumor (TURBT) is the primary treatment for early-stage bladder cancer, and early detection of tumor recurrence is vital for improving patient outcome. Non-invasive and reliable methods for monitoring molecular changes in urine represent a promising avenue to facilitate timely intervention and effective disease management.
Methods
In this ongoing prospective study, 95 patients with early-stage bladder cancer were recruited, whose urine samples were collected prior to TURBT. Afterward, patients were advised to provide urine samples during follow-up visits. PredicineCARE, a targeted next-generation sequencing (NGS) liquid biopsy assay, was employed to identify somatic alterations in urinary tumor DNA (utDNA). Based on these alterations, the tumor fraction was assessed to identify molecular recurrence in the patients.
Results
Out of the 95 patients, 48 were diagnosed with non-muscle invasive bladder cancer (NMIBC) and 47 with muscle invasive bladder cancer (MIBC). The genes that showed the most frequent variations in NMIBC patients were
Conclusions
The results of this study confirm the validity of utilizing a utDNA assay to detect molecular recurrence in early-stage bladder cancer patients who have undergone TURBT treatment, which can be instrumental in facilitating early detection of tumor recurrence and guiding treatment decisions. These findings underscore the enormous potential of urine-based NGS assays for urothelial cancer detection and disease surveillance.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.